Boehringer Ingelheim Venture Fund

What they do

Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy.

What they look for

The Boehringer Ingelheim Venture Fund is committed to advancing scientific innovation by investing in first-in-class, disease-modifying therapeutics across various modalities. Our investments aim to redefine standards of care and drive Boehringer Ingelheim's expansion into groundbreaking medical treatments.

Stage

Seed, Series A

Sectors

Healthcare

Based

Ingelheim Am Rhein, DE